• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

Pharmacovigilance Analytics

Your best resource for PV analytics news, content and innovation!

  • Home
  • Pharmacovigilance Analytics
    • Sources of data
    • Methods and tools
  • Signal Detection
  • News
  • Opinion
  • About
  • Glossary

disproportional recording

Disproportional Recording vs Disproportional Reporting

April 1, 2018 by Jose Rossello Leave a Comment

Signals of Disproportional Recording – Seriously?

I have read with great interest a paper recently published in Drug Safety journal (Zhou X, Douglas IJ, Shen R, Bate A. Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database. Drug Saf. https://doi.org/10.1007/s40264-017-0626-y). As always, I read with attention all papers authored by Andrew Bate and his team.

Something in the paper that called my attention was the concept of “Signals of Disproportional Recording (SDRs)“. I read it first in the abstract, and my first thought was that it was an error, and the authors were actually referring to Signals of Disproportionate Reporting (SDRs). Signals of disproportionate reporting are understood as statistical associations between medicinal products and adverse events i.e. drug-event pairs. When a SDR is identified for a medicinal product, this adverse event is reported relatively more frequently in association with this medicinal product than with other medicinal products (Practical Aspects of Signal Detection in Pharmacovigilance : Report of CIOMS Working Group VIII. CIOMS, Geneva, 2010).

Of course, it was not a mistake. The Analysis Methods section of the paper explains it clearly:

Incidence rate ratios (IRRs) are calculated by comparing the rate of events in a given post-exposure period (risk period) with the rate of events in unexposed periods absent of the exposure (all other observed times). In a signal screening framework, statistical uncertainty is examined based on the 95% confidence interval (CI) of the IRR estimates. Specifically, when the lower bound of the 95% CI of the IRR estimate is > 1, this is considered a positive finding and is a Signal of Disproportional Recording (SDR) analogous to SDRs in spontaneous reporting, which are findings of potential interest that have not undergone clinical review to be considered signals of suspected causality.

But I wanted to know more about this new concept. Who was the first one to use it on a scientific communication? I did a little research and found one reference for the same concept: A. Bate. Tuning Epidemiological Study Design Methods for Exploratory Data Analysis in Real World Data. Abstract presented in 15th ISOP Annual Meeting “Cubism in Pharmacovigilance” Prague, Czech Republic 27-30 October, 2015.

So, it is clear that the concept of signal of disproportional recording has been first used by Andrew Bate. The concept is brilliant. The finding of an adverse event-drug pair in an electronic health record happens because someone recorded it, independently of whether or not is was also reported.

Even though secondary use of electronic healthcare records (EHR) and insurance claims data for hypothesis testing has occurred for many decades, signal detection activities to identify potential drug safety issues has historically focused primarily on spontaneous reports. But there is an increasing interest on using EHR for signal detection in pharmacovigilance. Electronic health records exhibit special characteristics (longitudinal nature, partially unstructured data) that is requiring to adapt old analytics to this new framework, and even create new methods and concepts (Zorych I, Madigan D, Ryan P, Bates A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res 2013; 22(1):39-56). That is, the analytic techniques used for the analysis of drug-event (or drug-outcome) pairs in spontaneous reporting of adverse events, are not directly applicable to EHR and claims data. Creative thinking and new research are welcome in this area.

The paper is interesting, not only for using “disproportional recording”, which is anecdotal. It explores how to adapt and evaluate the self-controlled case series method and its use in claims and electronic medical records databases, for the challenging aspect of signal detection in the framework of  recently approved products. You will find an interesting discussion on the appropriate risk period selection method, which may be different in drug safety signal detection, than in formal hypothesis-testing studies.

The authors conclude that self-controlled case series method may be useful for safety signal detection in EHRs, and that early identification of previously unknown safety signals may be possible shortly after a new product is launched. Performance of this method varies by the nature of both exposure and event pair and their anticipated association.

 

Jose Rossello

Filed Under: Signal Detection Tagged With: disproportional recording, disproportional reporting, SDR, signal detection

Primary Sidebar

Subscribe in a reader

Featured News / Posts

Post-Randomization vs On Treatment Made All the Difference

Post-Randomization vs On Treatment Made All the Difference

The Food and Drug Administration (FDA) recently requested withdraw of Belviq® … [Read More...] about Post-Randomization vs On Treatment Made All the Difference

Pharmacovigilance Audits/Inspections and PV Analytics!

Disclaimer: This article is written by a Safety Physician to provide … [Read More...] about Pharmacovigilance Audits/Inspections and PV Analytics!

Artificial Intelligence in pharmacovigilance? What a challenge!

Abstract Pharmaceutical industry, and more particularly pharmacovigilance, … [Read More...] about Artificial Intelligence in pharmacovigilance? What a challenge!

Knowledge Graphs,  Semantic Web and Drug Safety

Knowledge Graphs, Semantic Web and Drug Safety

Second part of: Mining PubMed for Drug Induced Acute Kidney Injury When I … [Read More...] about Knowledge Graphs, Semantic Web and Drug Safety

Review of Safety in FDA Medical Reviews

Review of Safety in FDA Medical Reviews

Analysis of the latest review of safety sections for new drug applications (NDAs … [Read More...] about Review of Safety in FDA Medical Reviews

Mining PubMed for Drug Induced Acute Kidney Injury

Mining PubMed for Drug Induced Acute Kidney Injury

Enhancing signal detection capabilities beyond regular literature … [Read More...] about Mining PubMed for Drug Induced Acute Kidney Injury

Top 7 Predictive Model Applications in Drug Safety and Pharmacovigilance

As drug safety and pharmacovigilance organizations develop more sophisticated … [Read More...] about Top 7 Predictive Model Applications in Drug Safety and Pharmacovigilance

The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

Peter J Pitts, President of the Center for Medicine in the Public Interest, and … [Read More...] about The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

Disproportional Recording vs Disproportional Reporting

Disproportional Recording vs Disproportional Reporting

Signals of Disproportional Recording - Seriously? I have read with great … [Read More...] about Disproportional Recording vs Disproportional Reporting

Deep Learning, Machine Learning, and Artificial Intelligence – What are the Differences?

In this video, Bernardo F. Nunes explains how these 3 concepts (artificial … [Read More...] about Deep Learning, Machine Learning, and Artificial Intelligence – What are the Differences?

  • How Organizations Use Social Media For Pharmacovigilance
  • Twitter, Safety and Pharmacovigilance: All Papers Retrieved using PubMed
  • Real World Evidence (RWE): Predictive Analytics to Impact Patient Safety

RSS From Nature journal

  • Prediction of pharmacological activities from chemical structures with graph convolutional neural networks
  • Identifying side effects of commonly used drugs in the treatment of Covid 19
  • Evaluation of FGFR inhibitor ASP5878 as a drug candidate for achondroplasia
  • Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta-analysis of randomized clinical trials
  • Progress in the mechanism and targeted drug therapy for COPD

Copyright © 2021 · News Pro on Genesis Framework · WordPress · Log in